Search

Your search keyword '"Alegre, Adrián"' showing total 24 results

Search Constraints

Start Over You searched for: Author "Alegre, Adrián" Remove constraint Author: "Alegre, Adrián" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
24 results on '"Alegre, Adrián"'

Search Results

1. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

2. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

3. Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)

4. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

5. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

6. COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant

7. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.

8. Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real‐world setting.

9. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma. Results of the Compassionate Use or the Expanded Access Program in Spain

11. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

12. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort

13. Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

14. Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

15. P-090: Immune biomarkers of survival and infectionrelated mortality in multiple myeloma (MM) patients treated with lenalidomide and dexamethasone (Rd)

16. Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

17. Therapeutic Efficacy of a Plasma Rich in Growth Factors Gel Combined with Fractional Ablative Laser in the Management of Post-acne Scars.

18. Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

19. Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

21. COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies

22. Impact of the COVID-19 Pandemic on the Incidence Registry of Hematological Neoplasms in the Region of Madrid (Spain). Preliminary Report of 2014-2021

24. Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial.

Catalog

Books, media, physical & digital resources